Nanjing Legend Biotech Co., Ltd.

Legend Biotech Ireland Limited

Nanjing Genscript Biotech Co., Ltd.

Nanjing Silergy Micro Technology Co., Ltd.

Wang Zhang

Shu Wu

Shuai Yang

Chuan-Chu Chou

Yafeng Zhang

Qing Zhang

Yun Zhang

Zhen Zhang

Zhongdao Li

Tailan Zhan

Yuanyuan Peng

Zhenyu Liu

Dongliang Wang

Lixin Song

Fangliang Zhang

Yunlei Liu

Junyan Sun

An Tang

Xiaojie Tu

Tao Zhao

Chenyu Shu

Sujuan Wang

Ruidong Hao

Qi Pan

Provided herein are anti-DLL3 chimeric antigen receptors (CARs), DLL3 binding proteins and uses of such CARs or DLL3 binding proteins in the treatment of DLL3 associated disorders, such as small cell lung cancer.

Anti-DLL3 chimeric antigen receptors and uses thereof

Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Single-domain antibodies against CLL1 and constructs thereof

A power conversion module can include: an i-th level structure comprising 2basic units, a second terminal of each basic unit in each level structure respectively connected to first terminals of two basic units in a next level structure, where a first terminal of a first basic unit in a first-level structure is used as a first terminal of the power conversion module; an N-th level structure comprising 2balance units, where second terminals of each balance unit are connected as a second terminal of the power conversion module, and second terminals of each basic unit in an (N−1)th level structure are respectively connected to first terminals of two balance units in the N-th level structure; and where each basic unit comprises a switched capacitor circuit, N is a positive integer greater than or equal to 2, i is a positive integer, and 1≤i≤N−1.

Power conversion module and power converter

Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine. Further, by means of the targeting specificity of the antibody, the targeted transport of the cytokine is effectively enhanced, and cytotoxicity is attenuated, thereby obtaining better anti-tumor potential.

Fusion protein dimer using antibody Fc region as backbone and use thereof

The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.

Single-domain antibodies against LAG-3 and uses thereof

Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against TIGIT

Growing community of inventors

Jiangsu, China

Wang Zhang